SOUTH SAN FRANCISCO, California, June 7, 2017 /PRNewswire/ -- ShangPharma Innovation, Inc. (SPII) announced the addition of David Spellmeyer, PhD and Robert Lutz, PhD to its Executive-In-Residence (EIR) team.
The EIR team provides SPII with expert advice on a wide range of business, scientific, and strategic topics. This includes the identification and assessment of novel opportunities for early-stage equity investments and new venture incubator tenants at SPII's San Francisco Bay Area facility. Drs. Spellmeyer and Lutz will also participate in the negotiation and management of collaborations, licenses, and partnerships.
Dr. Spellmeyer is a biotechnology executive with 25 years of broad experience in the life sciences industry. He heads Interlaken Associates where he advises early-stage companies and investors on corporate and technical strategy, product development, commercialization, and funding. He previously served as CTO & CIO at Nodality and in research leadership roles at both large and small companies. Dr. Spellmeyer received his BS in computer science and chemistry from Purdue University and his PhD in theoretical organic chemistry from UCLA. He completed postdoctoral training in pharmaceutical chemistry at UCSF, where he is an adjunct Associate Professor.
Dr. Lutz founded Crescendo BioPharma Consulting and provides strategic, tactical, and operational expertise to help meet the needs of emerging biotechnology and pharmaceutical companies worldwide. He focuses on guiding transitions from discovery to clinical proof-of-concept. Previously, for more than 20 years, he was employed at Immunogen, Inc., last holding the position of Vice President, Translational Research and Development. Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.
"We are pleased to add Dr. Spellmeyer and Dr. Lutz to our EIR ranks. Having access to such experienced and successful entrepreneurs will greatly benefit our innovation practice at all stages of biomedical R&D," said Dr. Walter H. Moos, CEO of SPII.
About ShangPharma Innovation
ShangPharma Innovation facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its ecosystem of collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at academic and major medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing.
FOR MORE INFORMATION
ShangPharma Innovation, Inc. www.ShangPharmaInnovation.com [email protected]
Advertisement
The EIR team provides SPII with expert advice on a wide range of business, scientific, and strategic topics. This includes the identification and assessment of novel opportunities for early-stage equity investments and new venture incubator tenants at SPII's San Francisco Bay Area facility. Drs. Spellmeyer and Lutz will also participate in the negotiation and management of collaborations, licenses, and partnerships.
Advertisement
Dr. Spellmeyer is a biotechnology executive with 25 years of broad experience in the life sciences industry. He heads Interlaken Associates where he advises early-stage companies and investors on corporate and technical strategy, product development, commercialization, and funding. He previously served as CTO & CIO at Nodality and in research leadership roles at both large and small companies. Dr. Spellmeyer received his BS in computer science and chemistry from Purdue University and his PhD in theoretical organic chemistry from UCLA. He completed postdoctoral training in pharmaceutical chemistry at UCSF, where he is an adjunct Associate Professor.
Dr. Lutz founded Crescendo BioPharma Consulting and provides strategic, tactical, and operational expertise to help meet the needs of emerging biotechnology and pharmaceutical companies worldwide. He focuses on guiding transitions from discovery to clinical proof-of-concept. Previously, for more than 20 years, he was employed at Immunogen, Inc., last holding the position of Vice President, Translational Research and Development. Dr. Lutz received his BS and PhD in biochemistry from the University of New Hampshire and Brandeis University, respectively, and was a postdoctoral fellow at the Eleanor Roosevelt Institute.
"We are pleased to add Dr. Spellmeyer and Dr. Lutz to our EIR ranks. Having access to such experienced and successful entrepreneurs will greatly benefit our innovation practice at all stages of biomedical R&D," said Dr. Walter H. Moos, CEO of SPII.
About ShangPharma Innovation
ShangPharma Innovation facilitates and accelerates drug discovery, focusing on both therapeutics and technology platforms, and offers funding, incubator space, and other support to its ecosystem of collaborators, partners, and tenants. This includes sponsoring proof-of-concept research at academic and major medical centers, research institutes, and seed-stage start-ups, leading to industry collaborations and venture capital financing.
FOR MORE INFORMATION
ShangPharma Innovation, Inc. www.ShangPharmaInnovation.com [email protected]
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/shangpharma-innovation-names-new-executives-in-residence-300469910.html
SOURCE ShangPharma Corporation
